Cargando…

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

BACKGROUND: Uterine serous papillary carcinoma (USPC) is a biologically aggressive variant of endometrial cancer. We investigated the expression of Serum Amyloid A (SAA) and evaluated its potential as a serum biomarker in USPC patients. METHODS: SAA gene and protein expression levels were evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocco, E, Bellone, S, El-Sahwi, K, Cargnelutti, M, Casagrande, F, Buza, N, Tavassoli, F A, Siegel, E R, Visintin, I, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720219/
https://www.ncbi.nlm.nih.gov/pubmed/19536090
http://dx.doi.org/10.1038/sj.bjc.6605129
_version_ 1782170119293632512
author Cocco, E
Bellone, S
El-Sahwi, K
Cargnelutti, M
Casagrande, F
Buza, N
Tavassoli, F A
Siegel, E R
Visintin, I
Ratner, E
Silasi, D-A
Azodi, M
Schwartz, P E
Rutherford, T J
Pecorelli, S
Santin, A D
author_facet Cocco, E
Bellone, S
El-Sahwi, K
Cargnelutti, M
Casagrande, F
Buza, N
Tavassoli, F A
Siegel, E R
Visintin, I
Ratner, E
Silasi, D-A
Azodi, M
Schwartz, P E
Rutherford, T J
Pecorelli, S
Santin, A D
author_sort Cocco, E
collection PubMed
description BACKGROUND: Uterine serous papillary carcinoma (USPC) is a biologically aggressive variant of endometrial cancer. We investigated the expression of Serum Amyloid A (SAA) and evaluated its potential as a serum biomarker in USPC patients. METHODS: SAA gene and protein expression levels were evaluated in USPC and normal endometrial tissues (NEC) by real-time PCR, immunohistochemistry (IHC), flow cytometry and by a sensitive bead-based immunoassay. SAA concentration in 123 serum samples from 51 healthy women, 42 women with benign diseases, and 30 USPC patients were also studied. RESULTS: SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by RT–PCR=162 vs 2.21; P=0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro. SAA concentrations (μg ml(−1)) had a median (95% CIs) of 6.0 (4.0–8.9) in normal healthy females and 6.0 (4.2–8.1) in patients with benign disease (P=0.92). In contrast, SAA values in the serum of USPC patients had a median (95% CI) of 15.6 (9.2–56.2), significantly higher than those in the healthy group (P=0.0005) and benign group (P=0.0006). Receiver operating characteristics (ROC) analysis of serum SAA to classify advanced- and early-stage USPC yielded an area under the ROC curve of 0.837 (P=0.0024). CONCLUSION: SAA is not only a liver-secreted protein but is also a USPC cell product. SAA may represent a novel biomarker for USPC to assist in staging patients preoperatively, and to monitor early-disease recurrence and response to therapy.
format Text
id pubmed-2720219
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27202192010-07-21 Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer Cocco, E Bellone, S El-Sahwi, K Cargnelutti, M Casagrande, F Buza, N Tavassoli, F A Siegel, E R Visintin, I Ratner, E Silasi, D-A Azodi, M Schwartz, P E Rutherford, T J Pecorelli, S Santin, A D Br J Cancer Molecular Diagnostics BACKGROUND: Uterine serous papillary carcinoma (USPC) is a biologically aggressive variant of endometrial cancer. We investigated the expression of Serum Amyloid A (SAA) and evaluated its potential as a serum biomarker in USPC patients. METHODS: SAA gene and protein expression levels were evaluated in USPC and normal endometrial tissues (NEC) by real-time PCR, immunohistochemistry (IHC), flow cytometry and by a sensitive bead-based immunoassay. SAA concentration in 123 serum samples from 51 healthy women, 42 women with benign diseases, and 30 USPC patients were also studied. RESULTS: SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by RT–PCR=162 vs 2.21; P=0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro. SAA concentrations (μg ml(−1)) had a median (95% CIs) of 6.0 (4.0–8.9) in normal healthy females and 6.0 (4.2–8.1) in patients with benign disease (P=0.92). In contrast, SAA values in the serum of USPC patients had a median (95% CI) of 15.6 (9.2–56.2), significantly higher than those in the healthy group (P=0.0005) and benign group (P=0.0006). Receiver operating characteristics (ROC) analysis of serum SAA to classify advanced- and early-stage USPC yielded an area under the ROC curve of 0.837 (P=0.0024). CONCLUSION: SAA is not only a liver-secreted protein but is also a USPC cell product. SAA may represent a novel biomarker for USPC to assist in staging patients preoperatively, and to monitor early-disease recurrence and response to therapy. Nature Publishing Group 2009-07-21 2009-06-16 /pmc/articles/PMC2720219/ /pubmed/19536090 http://dx.doi.org/10.1038/sj.bjc.6605129 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Cocco, E
Bellone, S
El-Sahwi, K
Cargnelutti, M
Casagrande, F
Buza, N
Tavassoli, F A
Siegel, E R
Visintin, I
Ratner, E
Silasi, D-A
Azodi, M
Schwartz, P E
Rutherford, T J
Pecorelli, S
Santin, A D
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title_full Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title_fullStr Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title_full_unstemmed Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title_short Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
title_sort serum amyloid a (saa): a novel biomarker for uterine serous papillary cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720219/
https://www.ncbi.nlm.nih.gov/pubmed/19536090
http://dx.doi.org/10.1038/sj.bjc.6605129
work_keys_str_mv AT coccoe serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT bellones serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT elsahwik serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT cargneluttim serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT casagrandef serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT buzan serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT tavassolifa serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT siegeler serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT visintini serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT ratnere serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT silasida serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT azodim serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT schwartzpe serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT rutherfordtj serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT pecorellis serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer
AT santinad serumamyloidasaaanovelbiomarkerforuterineserouspapillarycancer